guideline for immune thrombocytopenia The American Society of Hematology 2011 evidence-based practice

Immune thrombocytopenia (ITP) is commonly encountered in clinical practice. In 1996 theAmerican Society of Hematology published a landmark guidance paper de-signed to assist clinicians in the management of this disorder. Since 1996 there have been numerous advances in the management of both adult and pediatric ITP. These changes mandated an update in the guidelines. This guideline uses a rigorous, evidence-based approach to the location, interpretation, and presentation of the available evidence. We have en-deavored to identify, abstract, and present all available methodologically rigorous data informing the treatment of ITP. Weprovideevidence-basedtreatmentrec-ommendations using the GRADE system in those areas in which such evidence exists. We do not provide evidence in those areas in which evidence is lacking, or is of lower quality—interested readers are referred to a number of recent, consensus-based recommendations for expert opinion in these clinical areas. Our review identified the need for additional studies in many key areas of the therapy of ITP such as comparative studies of “front-line” therapy for ITP, the management of serious bleeding in patients with ITP, and studies that will provide guidance about which therapy should be used as salvage therapy for patients after failure of a first-line intervention. ( Blood . 2011;117(16):4190-4207)